Contrasting Arvinas (NASDAQ:ARVN) & Elevai Labs (NASDAQ:ELAB)

Arvinas (NASDAQ:ARVN) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Arvinas and Elevai Labs, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	0	2	11	0	2.85
Elevai Labs	0	0	0	0	0.00

Arvinas currently has a consensus target price of $56.08, indicating a potential upside of 575.70%. Given Arvinas’ stronger consensus rating and higher probable upside, analysts clearly believe Arvinas is more favorable than Elevai Labs.

Profitability

This table compares Arvinas and Elevai Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arvinas	-75.51%	-33.75%	-16.75%
Elevai Labs	-223.41%	-124.93%	-85.10%

Volatility & Risk

Arvinas has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, Elevai Labs has a beta of -2.93, indicating that its share price is 393% less volatile than the S&P 500.

Valuation and Earnings

This table compares Arvinas and Elevai Labs”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$263.40 million	2.17	-$198.90 million	($2.77)	-3.00
Elevai Labs	$2.45 million	1.11	-$4.30 million	($433.87)	-0.01

Elevai Labs has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Elevai Labs, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 22.2% of Elevai Labs shares are owned by institutional investors. 5.2% of Arvinas shares are owned by company insiders. Comparatively, 0.6% of Elevai Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Arvinas beats Elevai Labs on 12 of the 14 factors compared between the two stocks.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

About Elevai Labs

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.